Medscan Laboratory INC

Medscan Laboratory INC was paid $14.77M by Medicaid between Jan 2018 and Dec 2024, across 149 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 49% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in North Dakota

Rank by total paid#1 of 15

Median peer was paid$4K

This provider vs. median3,651×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	66,314	$2.20M
2019	72,941	$2.35M
2020	118,429	$3.05M
2021	166,699	$3.09M
2022	122,935	$1.72M
2023	83,665	$1.24M
2024incomplete	63,870	$1.12M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	49%	72,091	45,884	$7.21M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	9.1%	25,975	13,164	$1.35M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	8.3%	47,924	32,122	$1.23M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	7.9%	23,813	11,200	$1.17M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	5.7%	12,641	8,205	$836K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	4.8%	11,485	8,838	$709K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.5%	16,441	7,618	$217K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.3%	4,195	3,091	$194K
87632		<1%	1,577	1,342	$144K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	18,432	14,434	$93K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	5,780	2,871	$92K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	2,069	1,526	$83K

137 more codes

83970		<1%	9,304	$65K
84403		<1%	8,647	$53K
82670		<1%	8,449	$51K
80323		<1%	2,473	$49K
80061	Lipid panel	<1%	21,646	$47K
84270		<1%	11,514	$46K
82627		<1%	10,940	$43K
82607		<1%	17,363	$43K
84305		<1%	10,029	$39K
84481		<1%	13,138	$38K
87640		<1%	3,289	$37K
83001		<1%	8,499	$35K
84144		<1%	7,975	$35K
82533		<1%	11,026	$35K
80050	General health panel	<1%	4,705	$35K
84443	Thyroid stimulating hormone (TSH)	<1%	16,096	$35K
84146		<1%	7,591	$33K
80053	Comprehensive metabolic panel	<1%	20,509	$32K
81162		<1%	24	$31K
82747		<1%	9,908	$31K
83036	Hemoglobin; glycosylated (A1C)	<1%	19,435	$30K
83003		<1%	7,384	$28K
87541		<1%	1,686	$25K
87581		<1%	1,780	$25K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,690	$25K
87486		<1%	1,779	$25K
82728		<1%	11,404	$25K
83002		<1%	7,889	$24K
84439		<1%	15,491	$24K
83520		<1%	9,680	$22K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	20,707	$21K
87481		<1%	2,060	$19K
87653		<1%	2,075	$18K
83735		<1%	12,637	$17K
83540		<1%	14,694	$16K
87631		<1%	256	$11K
84153		<1%	4,055	$11K
82746		<1%	4,915	$10K
81435		<1%	24	$10K
81436		<1%	24	$10K
81317		<1%	23	$10K
87500		<1%	841	$7K
80359		<1%	2,450	$7K
80335		<1%	2,458	$7K
80346		<1%	2,571	$7K
80332		<1%	2,471	$7K
83880		<1%	1,943	$7K
80348		<1%	2,564	$6K
80354		<1%	2,467	$6K
80338		<1%	2,449	$6K
80372		<1%	2,466	$6K
80362		<1%	2,561	$6K
80368		<1%	2,496	$6K
80357		<1%	2,446	$6K
80373		<1%	2,557	$6K
80366		<1%	2,463	$6K
80369		<1%	2,473	$6K
80360		<1%	2,440	$6K
80324		<1%	2,480	$6K
87641		<1%	762	$6K
80342		<1%	2,492	$5K
83698		<1%	2,954	$5K
82785		<1%	615	$5K
87150		<1%	568	$5K
82172		<1%	2,629	$5K
80371		<1%	2,032	$5K
83090		<1%	4,196	$5K
80345		<1%	2,458	$5K
80350		<1%	1,942	$4K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	410	$4K
83550		<1%	5,557	$4K
80349		<1%	1,121	$4K
80321		<1%	662	$3K
80074		<1%	240	$3K
86376		<1%	1,820	$3K
81319		<1%	24	$3K
80361		<1%	957	$3K
80356		<1%	926	$3K
80365		<1%	942	$3K
80353		<1%	843	$3K
83992		<1%	671	$3K
86141		<1%	509	$3K
80358		<1%	740	$2K
84550		<1%	5,329	$2K
86431		<1%	4,110	$1K
86800		<1%	764	$1K
83615		<1%	2,771	$1K
86003		<1%	582	$1K
84466		<1%	1,353	$946.23
80076		<1%	233	$917.80
80355		<1%	2,108	$905.10
80164		<1%	75	$638.97
80048	Basic metabolic panel (calcium, ionized)	<1%	764	$585.77
80339		<1%	263	$487.92
84436		<1%	1,087	$485.14
86803		<1%	110	$457.59
82248		<1%	822	$417.53
81001		<1%	482	$312.93
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	217	$299.14
82570		<1%	583	$295.78
86140		<1%	1,642	$292.51
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	216	$284.14
86709		<1%	66	$242.85
87340		<1%	66	$222.92
84480		<1%	713	$205.00
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	200	$203.38
83701		<1%	138	$203.16
82550		<1%	468	$174.11
83525		<1%	465	$156.66
85652		<1%	1,256	$148.29
86592		<1%	82	$146.98
80375		<1%	63	$141.50
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	727	$112.02
82043		<1%	162	$92.73
86038		<1%	18	$77.35
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	195	$53.84
81003		<1%	111	$32.18
84311		<1%	192	$16.20
36415	Collection of venous blood by venipuncture	<1%	928	$15.59
83986		<1%	192	$11.75
81025		<1%	15	$10.77
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	36	$9.13
83690		<1%	182	$5.51
82150		<1%	292	$5.18
85027		0%	23	$0.00
83721		0%	140	$0.00
84702		0%	15	$0.00
84681		0%	171	$0.00
82977		0%	133	$0.00
81408		0%	24	$0.00
84202		0%	34	$0.00
83695		0%	134	$0.00
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	0%	93	$0.00
81406		0%	24	$0.00
81404		0%	24	$0.00
83655		0%	34	$0.00
81405		0%	24	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHOWARD, WILLIAM (CEO)

Same official

Other billing entities under HOWARD, WILLIAM

Full network →

Provider	Location	Paid
Altru Diagnostics, INC	Houston, TX	$5.09M
William S Howard DDS INC	Tellico Plains, TN	$114K
General Internal Medicine, PA	Dallas, TX	$54K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.